HMW-HA was significantly superior in cost effectiveness and cost efficacy to all other instillation regimes .
Bladder pain syndrome/interstitial cystitis ( BPS/IC ) is a chronic disease characterised by persistent irritating micturition symptoms and pain .
The objective was to compare the clinical efficacy of currently available products for intravesical therapy of BPS/IC and to assess their pharmacoeconomic impact .
Prophylactic vesical instillations with 0.2% chondroitin sulfate may reduce symptoms of acute radiation cystitis in patients undergoing radiotherapy for gynecological malignancies
Introduction and hypothesisWe studied the feasibility and efficacy of intravesical instillations with 40 ml chondroitin sulfate 0.2 % solution to prevent or reduce acute radiation cystitis in women undergoing pelvic radiotherapy . Methods In a comparative pilot study in 20 patients , half of the patients received instillations . Instillations ' bother was measured with visual analog scores ( VAS , 0–10 ) ; bladder pain , with VAS ; micturition-related quality of life , with the urogenital distress inventory ( UDI ) . Results One of the instilled patients discontinued the instillations . The first median “ acceptability”-VAS was 0 ( range , 0–3 ) ; the last median was 1 ( range , 0–3 ) . “ Bladder pain”-VAS peaked halfway in the treatment among controls ( median , 1 ; range , 0–5 ) and after treatment in the instilled patients ( median , 1 ; range , 1–3 ) . UDI scores showed over time median follow-up scores at or above median baseline scores in controls and at or below median baseline scores in instilled patients . Conclusion Intravesical instillations with chondroitin sulfate 0.2 % solution may decrease the bother related to bladder symptoms and are well tolerated
HMW-HA was significantly superior in cost effectiveness and cost efficacy to all other instillation regimes .
Bladder pain syndrome/interstitial cystitis ( BPS/IC ) is a chronic disease characterised by persistent irritating micturition symptoms and pain .
The objective was to compare the clinical efficacy of currently available products for intravesical therapy of BPS/IC and to assess their pharmacoeconomic impact .